Emperador Inc.

Disclaimer: The research and recommendation below were generated by Claude Fable. Please treat this as one input for your own research — not as the sole basis for any decision to buy or sell a stock.

Last checked: July 19, 2026
Price: 15.4000
Trading status: Normal
Recommendation: Sell (shrinking profits at a premium multiple; thin float)Sell
Committee call: Sell
Indices: PSEi

Analysis

EMI - Emperador Inc.

One-line summary: The world's biggest brandy maker (plus Whyte & Mackay Scotch) has watched net income shrink for four straight years while the stock still trades at a rich multiple, and the shares are dual-listed and thinly traded, making this an expensive bet on a turnaround that hasn't shown up in the numbers yet.

Snapshot


Reviewed	July 19, 2026
Index membership	PSEi
Price at review	P15.40 (July 17, 2026 close; 52-week range P14.78-P16.78)
Recommendation	Sell (expensive multiple on shrinking earnings, thin liquidity, weak dividend trend)
Market cap	P242.6B (15.7B shares)
Trailing P/E	~61.6x
Estimated forward P/E (2026)	~41.8x
Dividend (2026)	P0.14/share, ~0.88% yield (ex January 19, 2026; paid January 29, 2026)
P/B	~2.4x
Debt	Moderate and rising (D/E ~0.40 in 2025, up from ~0.28-0.33 in 2021-2023)

Core business: brandy giant, whisky diversification

Emperador is the world's largest brandy producer by volume (Emperador, The Bar, Fundador) and, through Whyte & Mackay, owns a Scotch whisky business (Whyte & Mackay blend, The Dalmore, Jura). Brandy is still the bulk of the business and is sold mostly in the Philippines, where it competes as a mass-market, value-priced spirit. Whisky is the smaller but higher-margin, faster-growing piece: Whyte & Mackay posted a record £96 million pre-tax profit in 2024, driven largely by The Dalmore's success, and the company is now redirecting capital toward whisky (warehouses, maturation sites) rather than brandy expansion.

Revenue and earnings: four straight years of shrinking profit

Revenue: P55.9B (2021), P62.8B (2022), P65.6B (2023), P61.6B (2024), P57.0B (2025). Net income: P10.0B (2021), P10.1B (2022), P8.7B (2023), P6.3B (2024), P3.9B (2025), a decline of roughly 61% from the 2022 peak. Net margin has compressed from ~16% (2022) to ~6.8% (2025). Management has repeatedly cited a "market inundated with cheap products as consumers seek for value" and stiff competition eroding the mass-market brandy business, consistent with the weak Philippine consumer spending backdrop (Visa's discretionary spending index was still below the 100 expansion threshold in Q1 2026).

The pattern within 2024 and 2025 is uneven, not a clean straight-line decline: H1 2024 net profit fell 19% to P3.8B before Q2 2024 alone recovered to P2.1B, and Q1 2025 net income rose 6.5% to P1.85B, yet full-year 2025 net income still ended down about 39% from 2024, implying a sharp slowdown in the back half of the year. Q1 2026 net income was P1.93B, up a modest 4.45% against that already-recovering Q1 2025 base, on P13.3B revenue and 6% brandy-and-whisky sales growth. That is not yet evidence the earnings decline has reversed. It is a flat comp against a quarter that itself was a recovery blip inside a longer downtrend.

Dividend sustainability: shrinking payout, rising payout ratio

Per-share dividend: P0.29 (2023), P0.24 (2024), P0.19 (2025), P0.1351 (declared for 2026, ex January 19, paid January 29, 2026), a third straight annual cut. Despite the shrinking absolute payout, the payout ratio has climbed from ~54% (2023) to ~62% (2024) to ~80% (2025) because earnings are falling faster than the dividend is being cut. Free cash flow coverage is worse: FCF was negative in 2024 (-P2.2B against P3.9B in dividends paid, meaning the dividend was funded from debt or cash reserves, not operations) and only P0.3B in 2025 against P3.1B in dividends paid, another shortfall. This is not a dividend investors should expect to hold at current levels; a fourth consecutive cut is the more likely path unless free cash flow recovers materially.

ROE: collapsing, not just cyclical

ROE: 13.9% (2021), 12.2% (2022), 9.7% (2023), 6.6% (2024), 3.8% (2025). ROA fell in step, from 7.0% to 2.8%. Debt/equity has crept up over the same period (0.33 to 0.40), so leverage is not masking the decline, the underlying business is earning less on the capital invested in it, full stop. A brandy-and-whisky business earning under 4% on equity is earning far below its cost of capital.

Free cash flow: capex-heavy, dividend barely covered

Operating cash flow: P16.4B (2021), P8.1B (2022), P7.2B (2023), P5.3B (2024), P6.9B (2025). Capex ramped from P1.7B (2021) to P4.0-7.5B (2022-2024) as whisky maturation and brandy production facilities were built out, before easing slightly to P6.7B in 2025. Free cash flow: P14.7B (2021), P4.1B (2022), P3.0B (2023), -P2.2B (2024), P0.3B (2025). The company has since guided capex sharply lower for 2026 (about P2.4B, roughly 40% below 2025's outlay), with more than half now earmarked for whisky warehouses and the rest for brandy production and distribution upgrades. If that capex reduction holds, FCF should improve mechanically, but it starts from a base where cash generation has not kept pace with the dividend for two straight years.

Capital allocation and ownership: tightly controlled, illiquid float

Andrew Tan's Alliance Global Group (AGI) holds a controlling 79.07% stake as of October 2025. Singapore's sovereign wealth fund GIC holds about 12% through its Arran Investment vehicle, and the Government Service Insurance System (GSIS) has been building a position, crossing 5.23% by December 2025. Tan personally bought about P1 billion of shares in 2025 (75 million shares at P13.30-13.32) even as the stock fell nearly 26% that year, a confidence signal from the controlling family, but one the market largely shrugged off.

The flip side of that concentrated ownership: public float sat at only 21.12% as of April 2025, close enough to the PSE's 20% minimum for index membership that analysts have flagged the risk directly, one describing EMI as "consistently ranked as one of the most illiquid index stocks." Emperador has also carried a secondary listing on the Singapore Exchange since July 2022 (ticker EMI on SGX), which fragments price discovery and trading volume across two markets rather than concentrating it on the PSE. Thin liquidity means wider spreads, harder entry and exit at scale, and index-eligibility risk if the float drifts under 20%: a breach would force passive PSEi funds to sell, adding further pressure on an already illiquid name.

Verdict at P15.40 (July 19, 2026)

Sell. Nothing material has changed in the week since the last review: the price drifted slightly lower (P15.40 versus P15.58), and no new quarterly results, dividend declarations, or PSE disclosures have landed since then, Q2 2026 results are not yet out. The thesis stands as written. This is a cheap-looking headline (a household brand, decades of dividends, a genuine bright spot in Whyte & Mackay) attached to a business whose net income has fallen roughly 61% since 2022 and whose ROE has cratered from 14% to under 4%, yet the stock still trades near 62x trailing earnings and 42x forward earnings. That is an expensive multiple for a shrinking-profit consumer name, not a value stock. The dividend has been cut three years running and free cash flow has failed to cover it for two of the last two years. Layer on a controlling family holding nearly 80% of the shares, a public float hovering barely above the PSE's minimum, and a secondary Singapore listing splitting whatever liquidity exists, and the risk/reward skews poorly: sell-side coverage stays net bearish, with more analysts rating the stock a Sell than a Buy and consensus 12-month targets clustered below the current price. Q1 2026's modest 4.45% net income growth is not yet proof the multi-year decline has turned; it is a flat comp against an already-recovering quarter.

What would change the call:

Buy trigger: two consecutive quarters of clear year-on-year net income growth against a normal (not recovering) base, confirming the earnings decline has genuinely reversed; or forward P/E compressing to the mid-teens or below without a further earnings cut; or free cash flow durably covering the dividend again (FCF comfortably above dividends paid for two straight years).
Sell trigger (if owned): a fourth consecutive annual dividend cut, public float falling below the 20% PSE threshold (index removal risk), or net income declining again below the 2025 full-year level.

Analysis, not financial advice.

Committee review (July 19, 2026)

Five investor lenses judged this page's facts independently, each strictly inside its own framework.

Lens	Signal	Confidence	Core argument
Ben Graham	Bearish	90	Trailing P/E (~61.6x) times P/B (2.4x) blows past Graham's 22.5 ceiling with no margin of safety; earnings down 61% from the 2022 peak, ROE down to 3.8%, and dividends have exceeded free cash flow in both 2024 and 2025.
Warren Buffett	Bearish	78	ROE collapsed from 13.9% to 3.8% and net income is down 61% from peak, while paying ~62x trailing earnings for a commoditized brandy business with no pricing power (management itself cites a market "inundated with cheap products").
Michael Burry	Bearish	80	The accounting still contradicts the "sustained growth momentum" framing: FCF swung from P14.7B to negative to a bare P0.3B while dividends kept going out funded by debt or reserves, not earnings, with leverage climbing (D/E 0.28 to 0.40).
Nassim Taleb	Bearish	75	FCF was negative in 2024 and near-zero in 2025 yet the dividend was still paid, funded by debt as leverage rose; ~42x forward earnings on a business with 3.8% ROE and three straight dividend cuts leaves little upside cushion against real downside.
Stanley Druckenmiller	Bearish	68	No confirmed catalyst: Q2 2026 results are not out yet, the guided capex relief hasn't shown up in a reported quarter, and Q1 2026's growth is a flat comp against an already-recovering base, not proof of a turn, against a soft Philippine consumer backdrop.

Conferred call: Sell (5 bearish, 0 neutral, 0 bullish). This matches the page's Recommendation exactly, no disagreement, and is unchanged from the July 12, 2026 run since no new financial data has landed. Against Brain/concepts/stock-trading-strategy-and-rules.md, there is still no catalyst and no setup quality here, only a hoped-for capex-relief and whisky-margin story that hasn't shown up in trailing numbers, consistent with a pass rather than a "cheap at the lows" trap worth buying into.

Shared flip trigger: durable, multi-quarter free cash flow that covers the dividend without new borrowing, alongside a real (not comp-driven) net income recovery.

Review history

Date	Price	Recommendation
July 10, 2026	15.52	Sell (expensive multiple on shrinking earnings, thin liquidity, weak dividend trend)
July 12, 2026	15.58	Sell (expensive multiple on shrinking earnings, thin liquidity, weak dividend trend)
July 19, 2026	15.40	Sell (expensive multiple on shrinking earnings, thin liquidity, weak dividend trend)